Chapter 21 - Rads, Systemic Tx H/N CA Flashcards
Benefit of adding chemo to radiation
Most common H/N chemo
Chemo potentiates effects of RT
Cisplatin- most common chemo for H/N chemorads
When to use postop chemorads
ECS, pos marg
Definitive H/N Rads doses
66-70 Gy definitive gross
Usually once/day 6-7 wk, 1.8-2.25 Gy per day
High risk elective neck- 60
Low risk- 54
Postop- 66
How radiation kills cells
ROS
Strand breaks
Who cannot be Tx with RT
Coll Vasc Dz
Hypersensitivity (Atax Telang)
Prego esp 1-2 tri
Xeroderma, Li Fraumeni INC risk secondary cancers
When to consider induction chemo
Hypo/Nasopharynx (can decrease risk of distant Mets, improved organ preservation)
Consider if delay in definitive chemorads and patient has upper airway obstruction/dental abscess
AE of Cisplatin
Hearing loss, renal failure, peripheral neuropathy, electrolytes, GI
AE of carboplatin
Electrolyte abnormalities, myelosuppression
AE of 5-FU
Mucositis, hand-foot syndrome, photosensitivity, maculopapular rash
AE of Paclitaxel
P neuro, arthralgia, myalgia
AE of Docetaxel
P neuro, edema, asthenia
Cetuximab AE
acneiform rash, dermatitis, hypomagnesemia, neutropenia
Which early stage H/N tumors should be treated with RT? Which should still get surgery?
RT (if T1-2, N0-1): tongue, tonsil, larynx, hypopharynx, can be considered RT candidates. Nasopharynx uses RT regardless of stage
No RT: salivary glands, FOM. Use surgery regardless of how early stage it is
When to add concurrent chemo to radiation for initial Tx of H/N cancers
T3-4, N2-3
When to offer adjuvant RT/chemo
margin positive, T3-4, multiple/bulky positive nodes, ECS, PNI, LVI, nodal disease in IV/V, oral cavity depth of invasion >2mm or close margins, recurrent dz treated with salvage surgery